Figure 4
From: Pentamethylquercetin (PMQ) reduces thrombus formation by inhibiting platelet function
Inhibitory effect of PMQ on agonist-induced platelet aggregation in human PRP and human washed platelets.
(A) PRP (3.0 × 108/ml) were pre-incubated with PMQ (10 μM, 20 μM and 40 μM) or a solvent control before the addition of ADP (2 μM) or collagen (0.5 μg/ml) to trigger platelet aggregation. Quantification of aggregation (%) was also shown in the right panel. (B) Washed platelets (3.0 × 108/ml) were pre-incubated with PMQ (10 μM, 20 μM and 40 μM) or a solvent control prior to the addition of collagen (0.5 μg/ml), thrombin (0.04 U/ml), or U46619 (0.3 μM) to trigger platelet aggregation. Quantification of aggregation (%) was also shown in the lower panel. Data are expressed as the mean ± SEM of four experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. vehicle.
